Pazopanib HCl (GW786034 HCl)

• CAT Number: A000401
• CAS Number: 635702-64-6
• Molecular Formula: C21H24ClN7O2S
• Molecular Weight: 473.98
• Purity: ≥95%
• Target: VEGFR
• Solubility: >11.9mg/mL in DMSO
• Storage: 3 years -20C powder
• IUPAC Name: 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride
• InChI: InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H
• InChIKey: MQHIQUBXFFAOMK-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N.Cl

Pazopanib HCl (GW786034 HCl)（Cat No.:A000401）is a potent, multi-targeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit. It is used primarily in the treatment of advanced renal cell carcinoma and soft tissue sarcomas by inhibiting angiogenesis, reducing tumor growth and metastasis. By targeting these key pathways, pazopanib disrupts the blood supply to tumors and impairs cancer cell survival. Its broad activity across multiple receptors makes it a valuable treatment option for managing advanced-stage cancers.